Wire Stories
-
445LESSENGERS Demonstrates 800G QSFP-DD and 400G QSFP112 Optical Transceivers
BASEL, Switzerland–(BUSINESS WIRE)–LESSENGERS Inc. (�LESSENGERS�), an innovative optical interconnect solution provider, announced today, a live demonstration of polymer-wired 800G QSFP-DD and 400G...
-
451India Over The Counter Drug Market to Grow at 7.85% Through 2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “India Over The Counter Drug Market, By Product Type, By Route of Administration, By Dosage Form, By Distribution Channel, By...
-
534J.P. Morgan to Acquire Renovite Technologies, Inc.
Acquisition of cloud-native payments technology firm to modernize infrastructure and create greater flexibility for the firm�s merchant acquiring capabilities globally NEW YORK...
-
499Announcement for �Innovation for Cool Earth Forum 9th Annual Meeting (ICEF2022)�
The international conference to discuss innovation, the key to solving global warming with experts from industry, academia, and government from the world...
-
605Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region
Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights. The Deal...
-
502Base Business Solutions and Uniphore Partner to Bring Emerging Technology to Vietnam�s CX Industry
The partnership will help boost contact center employee morale and provide superior customer experiences using Conversational AI and Automation HO CHI MINH...
-
481Chery Is Accompanied With Love at the Mid-Autumn Festival
WUHU, China–(BUSINESS WIRE)–China celebrates the Mid-Autumn Festival on September 10. On this day, all Chinese families will partake in eating a classic...
-
605ENHERTU� Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo...
-
705DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be featured in...
-
528BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations show breadth...
